

2015 Cancer Program Annual Report

J. Phillip Citta Regional Cancer Center
Community Medical Center
RWJBarnabas Health

A statistical report of cancer cases seen at Barnabas Health - Community Medical Center (CMC) in 2015. This data is benchmarked against the National Cancer Data Base. Some of the graphical representations include a breakdown of cases by Age, Gender, Race, as well as more site specific data.

Message from the Cancer Committee Chair

I am pleased to present the 2015 J. Phillip Citta Regional Cancer Center at Community Medical Center Annual Report. The Cancer Center was a proud member of the University of Pennsylvania Cancer Network in 2015 and together we worked at growing our program and offering more services as part of a multi-disciplinary comprehensive oncology program. These include resumption of on-site genetic risk counseling, CT-lung screening for patients at risk of developing lung cancer, and growing a research program to offer local patients access to innovative treatments in their local community.

This growth is on top of the already robust surgical, medical, and radiation oncology services that have led our area in terms of breadth and quality of oncologic treatment. The quality of these services has been demonstrated by the American College of Surgeons awarding their 2014 Outstanding Achievement Award to our cancer center – one of only 2 in the state to accomplish this.

Now our program continues to grow with our new relationship with Robert Wood Johnson Medical System. This report summarizes our 2015 statistics and program status.

Thank you.

Rajesh Iyer, MD.
Chairman, CMC Cancer Committee.

J. Phillip Citta

Regional Cancer Center

- Designated by the Commission on Cancer (CoC) of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program since 1986.
- 2014 Outstanding Achievement Award from CoC – only 2 hospitals in NJ and 75 in the nation.
- Recognized as one of the 100 Hospitals with a Great Oncology Program by Becker's Hospital Review.

Cancer Committee Members

Physician Members:

- **Rajesh Iyer, MD**, Cancer Committee Chairman, Radiation Oncology
- **David D'Ambrosia, MD**, Radiation Oncology (Alternate)
- **Stephen Kupferberg, MD**, Vice Chairman, Cancer Committee, ACoS Cancer Liaison, ENT
- **Bruce Peters, DO**, ENT (Alternate)
- **Chirag Shah, MD**, Hematology/Oncology, PI Medical Oncology Research
- **Gurpreet Lamba, MD**, Hematology/Oncology
- **Apurv Agrawal, MD**, Hematology/Oncology
- **Jorge Pardes, MD**, Radiology
- **Michael D'Angelo, MD**, Radiology (Alternate)
- **Mohammad Hafiz, MD**, Pathology Cancer Conference Coordinator
- **Ramesh Mahapatro, MD**, Pathology Cancer Conference (Alternate)
- **Jane Park, MD**, Surgery
- **Tarun Bhandari, MD**, Surgery (Alternate)
- **Marianne Holler, DO, F.A.C.O.I.**, Home Health / Hospice

Cancer Committee Members

Non Physician Members:

- **Robert Braun, MA, M.Ed., RN, OCN, RT (T)(R)**, VP Oncology Services
- **Marley Nicolas, RN, MSN**, Administrative Director, Medical-Surgical Nursing
- **Jonathan Gapilango, RN, MSN, OCN,CCRP, NE-BC**, Director, Inpatient Oncology, Oncology Research & Oncology Data Center
- **Lennette Gonzales, RN, MSHS,OCN, CCRP**, Oncology Research
- **Veronica Keough, BA, CTR**, Cancer Registry Interim Coordinator
- **Debbie Feeney, BA, CTR**, Cancer Registry (Alternate)
- **Cheryl O'Blek, RN, BSN,OCN, QI & Survivorship Coordinator**
- **Christina Dambroski, RN, OCN**, QI Coordinator (Alternate)
- **Sherry Laniado, MSW, LCSW**, Psychosocial Services Coordinator
- **Tracie B. Mathews, MSW, LCSW, OSW-C, CCIT, CPTH** , Psychosocial Services Coordinator (Alternate)
- **Terri Martin, RN, BSN, OCN, CBCN**, Nurse Navigator
- **Kathe Wright, MSN, RN-C**, Nurse Navigator (Alternate)
- **Karen Purcell, BS**, Community Outreach Coordinator
- **Anne, McGarry, MSW**, Community Outreach (Alternate)
- **Julie Gonzaga, RN, BSN, BC**, Oncology Nursing
- **Jane Krong, RN, BSN, OCN**, Oncology Nursing (Alternate)
- **Marianne Brown, RN, MSN, OCN**, Oncology Nursing (Alternate)
- **Dorothy Moloney, RN**, Home Health / Hospice (Alternate)
- **Kaitlin Kraft, MS GC**, Genetic Counselor
- **Veronica Gajda, RD, CSO**, Nutrition Services
- **Lynne Goldstein, PharmD, RPh**, Pharmacy Services
- **Melissa White**, American Cancer Society Navigator
- **Kimberly Gittines**, Health Systems Manager, American Cancer Society
- **Ray Howard**, Rehab Services
- **Jean Flaherty**, Marketing

CLASS OF CASE




Figure 1

RACE




Figure 2

STATISTICAL SUMMARY OF CANCER CASES AT CMC PATIENT DEMOGRAPHICS

Data from the American Cancer Society's *Facts and Figures for 2015* estimated that there will be over 1,658,370 new cancer cases in 2015, 51,410 will be diagnosed in New Jersey.

In 2015, there were 1433 new cancer cases accessioned at Community Medical Center (CMC).


Of the 1433 cases, the non-analytic cases include 247 that were seen for recurrent or progressive disease (Classes 30-38) and 28 cases that were pathology review cases (Class 43). The following statistical report is based on the remaining 1157 analytic cases, of which, 183 were diagnosed at CMC and went elsewhere for treatment (Class 00), 614 were diagnosed and treated at CMC (Classes 10-14) and 360 were diagnosed at another facility and referred to CMC for treatment (Classes 20-22). **Figure 1** represents a breakdown by class of case.

Medicare was the primary insurance coverage for 65% of patients followed by Managed Care at 25% and 5% Medicaid. Gender distribution revealed 58% females and 42% males. Race distribution included: White: 96%, Black: 3%, and other or unspecified race at 1%. **Figure 2** is a representation by gender and race.

SITE DISTRIBUTION

Figure 3 summarizes the top five analytical primary sites for 2015 which include lung, breast, melanoma, colon, and prostate.

TOP 5 SITES



The J. Phillip Citta
Regional Cancer Center
and Infusion Suite



Primary Site	Total (%)	Sex		Class of		Status		Stage						88	Unk
		M	F	Analy	NA	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV			
ORAL CAVITY & PHARYNX	25 (1.7%)	13	12	15	10	19	6	0	3	4	1	7	0	0	
Lip	2 (0.1%)	1	1	0	2	0	2	0	0	0	0	0	0	0	
Tongue	4 (0.3%)	3	1	1	3	3	1	0	0	0	0	1	0	0	
Salivary Glands	5 (0.3%)	1	4	5	0	5	0	0	2	2	0	1	0	0	
Floor of Mouth	1 (0.1%)	0	1	1	0	1	0	0	0	0	0	1	0	0	
Gum & Other Mouth	7 (0.5%)	3	4	4	3	5	2	0	1	2	0	1	0	0	
Tonsil	2 (0.1%)	2	0	1	1	2	0	0	0	0	0	1	0	0	
Oropharynx	2 (0.1%)	2	0	2	0	2	0	0	0	0	0	2	0	0	
Hypopharynx	2 (0.1%)	1	1	1	1	1	1	0	0	0	1	0	0	0	
DIGESTIVE SYSTEM	244 (16.7%)	124	120	209	35	156	88	2	38	56	39	49	5	20	
Esophagus	25 (1.7%)	16	9	17	8	9	16	0	2	5	0	6	0	4	
Stomach	15 (1.0%)	9	6	11	4	10	5	0	1	4	0	3	0	3	
Small Intestine	3 (0.2%)	2	1	2	1	3	0	0	0	0	1	0	0	1	
Colon Excluding Rectum	95 (6.5%)	41	54	85	10	70	25	0	20	31	17	17	0	0	
Cecum	23	10	13	23	0	17	6	0	6	9	4	4	0	0	
Appendix	1	0	1	1	0	1	0	0	1	0	0	0	0	0	
Ascending Colon	31	10	21	28	3	23	8	0	7	14	4	3	0	0	
Hepatic Flexure	1	1	0	1	0	0	1	0	0	0	0	1	0	0	
Transverse Colon	4	3	1	4	0	4	0	0	2	1	1	0	0	0	
Descending Colon	6	3	3	6	0	5	1	0	1	4	1	0	0	0	
Sigmoid Colon	16	9	7	16	0	12	4	0	3	3	7	3	0	0	
Large Intestine, NOS	13	5	8	6	7	8	5	0	0	0	0	6	0	0	
Rectum & Rectosigmoid	40 (2.7%)	22	18	38	2	31	9	2	11	7	10	8	0	0	
Rectosigmoid Junction	23	12	11	23	0	18	5	0	9	4	7	3	0	0	
Rectum	17	10	7	15	2	13	4	2	2	3	3	5	0	0	
Anus, Anal Canal & Anorectum	7 (0.5%)	1	6	6	1	7	0	0	0	4	2	0	0	0	
Liver & Intrahepatic Bile Duct	17 (1.2%)	11	6	14	3	9	8	0	1	1	2	0	2	8	
Liver	15	11	4	13	2	8	7	0	1	1	2	0	1	8	
Intrahepatic Bile Duct	2	0	2	1	1	1	1	0	0	0	0	0	1	0	
Gallbladder	3 (0.2%)	0	3	3	0	1	2	0	0	1	2	0	0	0	
Other Biliary	6 (0.4%)	4	2	4	2	1	5	0	0	0	0	1	2	1	
Pancreas	30 (2.1%)	17	13	26	4	14	16	0	3	3	4	13	0	3	
Peritoneum, Omentum & Mesentery	2 (0.1%)	1	1	2	0	1	1	0	0	0	1	1	0	0	
Other Digestive Organs	1 (0.1%)	0	1	1	0	0	1	0	0	0	0	0	1	0	
RESPIRATORY SYSTEM	272 (18.6%)	130	142	231	41	149	123	2	53	13	54	89	3	17	
Nose, Nasal Cavity & Middle Ear	3 (0.2%)	2	1	3	0	3	0	0	0	0	0	2	1	0	
Larynx	15 (1.0%)	10	5	14	1	13	2	2	3	1	2	3	1	2	
Lung & Bronchus	254 (17.4%)	118	136	214	40	133	121	0	50	12	52	84	1	15	
SOFT TISSUE	4 (0.3%)	2	2	2	2	3	1	0	1	1	0	0	0	0	
Soft Tissue (including Heart)	4 (0.3%)	2	2	2	2	3	1	0	1	1	0	0	0	0	
SKIN EXCLUDING BASAL & SQUAMOUS	113 (7.7%)	65	48	97	16	105	8	26	56	8	1	1	1	4	
Melanoma - Skin	108 (7.4%)	64	44	93	15	100	8	26	55	7	1	1	0	3	
Other Non-Epithelial Skin	5 (0.3%)	1	4	4	1	5	0	0	1	1	0	0	1	1	
BASAL & SQUAMOUS SKIN	3 (0.2%)	1	2	0	3	3	0	0	0	0	0	0	0	0	
Basal/Squamous cell carcinomas of Skin	3 (0.2%)	1	2	0	3	3	0	0	0	0	0	0	0	0	
BREAST	247 (16.9%)	2	245	201	46	228	19	19	85	60	25	10	0	2	
Breast	247 (16.9%)	2	245	201	46	228	19	19	85	60	25	10	0	2	
FEMALE GENITAL SYSTEM	103 (7.0%)	0	103	88	15	85	18	2	40	12	11	12	3	8	
Cervix Uteri	15 (1.0%)	0	15	12	3	12	3	0	2	6	1	2	0	1	
Corpus & Uterus, NOS	46 (3.1%)	0	46	44	2	43	3	2	32	2	3	3	0	2	
Corpus Uteri	43	0	43	41	2	41	2	2	31	2	3	1	0	2	
Uterus, NOS	3	0	3	3	0	2	1	0	1	0	0	2	0	0	
Ovary	28 (1.9%)	0	28	21	7	20	8	0	4	2	5	7	0	3	
Vagina	3 (0.2%)	0	3	3	0	2	1	0	1	1	0	0	0	1	
Vulva	8 (0.5%)	0	8	5	3	7	1	0	1	1	2	0	0	1	
Other Female Genital Organs	3 (0.2%)	0	3	3	0	1	2	0	0	0	0	0	3	0	
MALE GENITAL SYSTEM	99 (6.8%)	99	0	62	37	90	9	0	8	35	6	3	0	10	
Prostate	95 (6.5%)	95	0	59	36	86	9	0	6	35	6	3	0	9	
Testis	3 (0.2%)	3	0	2	1	3	0	0	2	0	0	0	0	0	
Penis	1 (0.1%)	1	0	1	0	1	0	0	0	0	0	0	0	1	
URINARY SYSTEM	92 (6.3%)	74	18	68	24	74	18	24	14	8	4	4	0	14	
Urinary Bladder	70 (4.8%)	60	10	51	19	58	12	21	12	6	0	1	0	11	
Kidney & Renal Pelvis	20 (1.4%)	13	7	15	5	14	6	2	2	2	4	2	0	3	
Ureter	2 (0.1%)	1	1	2	0	2	0	1	0	0	0	1	0	0	
EYE & ORBIT	1 (0.1%)	1	0	0	1	0	1	0	0	0	0	0	0	0	
Eye & Orbit	1 (0.1%)	1	0	0	1	0	1	0	0	0	0	0	0	0	
BRAIN & OTHER NERVOUS SYSTEM	26 (1.8%)	14	12	18	8	18	8	0	0	0	0	0	18	0	
Brain	17 (1.2%)	12	5	11	6	10	7	0	0	0	0	0	11	0	
Cranial Nerves Other Nervous System	9 (0.6%)	2	7	7	2	8	1	0	0	0	0	0	7	0	
ENDOCRINE SYSTEM	60 (4.1%)	17	43	51	9	60	0	0	30	2	5	4	1	9	
Thyroid	56 (3.8%)	14	42	50	6	56	0	0	30	2	5	4	0	9	
Other Endocrine including Thymus	4 (0.3%)	3	1	1	3	4	0	0	0	0	0	0	1	0	
LYMPHOMA	66 (4.5%)	33	33	50	16	54	12	0	16	10	5	6	1	12	
Hodgkin Lymphoma	6 (0.4%)	3	3	5	1	5	1	0	1	0	1	0	0	3	
Hodgkin - Nodal	5	2	3	4	1	5	0	0	0	0	1	0	0	3	
Hodgkin - Extranodal	1	1	0	1	0	0	1	0	1	0	0	0	0	0	
Non-Hodgkin Lymphoma	60 (4.1%)	30	30	45	15	49	11	0	15	10	4	6	1	9	
NHL - Nodal	35	16	19	23	12	27	8	0	3	8	4	4	0	4	
NHL - Extranodal	25	14	11	22	3	22	3	0	12	2	0	2	1	5	

Primary Site	Total (%)	Sex		Class of		Status		Stage					88	Unk
		M	F	Analy	NA	Alive	Exp	Stg 0	Stg I	Stg II	Stg III	Stg IV		
MELOMA	19 (1.3%)	10	9	11	8	14	5	0	0	0	0	0	11	0
Meloma	19 (1.3%)	10	9	11	8	14	5	0	0	0	0	0	11	0
LEUKEMIA	24 (1.6%)	19	5	14	10	15	9	0	0	0	0	0	14	0
Lymphocytic Leukemia	13 (0.9%)	9	4	7	6	10	3	0	0	0	0	0	7	0
Acute Lymphocytic Leukemia	1	1	0	0	1	1	0	0	0	0	0	0	0	0
Chronic Lymphocytic Leukemia	12	8	4	7	5	9	3	0	0	0	0	0	7	0
Myeloid & Monocytic Leukemia	11 (0.8%)	10	1	7	4	5	6	0	0	0	0	0	7	0
Acute Myeloid Leukemia	7	6	1	6	1	3	4	0	0	0	0	0	6	0
Chronic Myeloid Leukemia	3	3	0	0	3	2	1	0	0	0	0	0	0	0
Other Myeloid/Monocytic Leukemia	1	1	0	1	0	0	1	0	0	0	0	0	1	0
MESOTHELIOMA	6 (0.4%)	6	0	6	0	3	3	0	1	0	1	3	0	1
Mesothelioma	6 (0.4%)	6	0	6	0	3	3	0	1	0	1	3	0	1
MISCELLANEOUS	57 (3.9%)	34	23	40	17	32	25	0	0	0	0	0	40	0
Miscellaneous	57 (3.9%)	34	23	40	17	32	25	0	0	0	0	0	40	0

Table 1 (cont.)

Table 2 & 3 summarize five primary sites for 2015 by gender and compares CMC's actual cases and the estimated figures from the American Cancer Society (ACS).

MALES		
	CMC	ACS
Prostate	12%	26%
Lung	21%	14%
Colon & Rectum	12%	8%
Bladder	9%	7%
Melanoma	11%	5%

Table 2

FEMALES		
	CMC	ACS
Breast	30%	29%
Lung	17%	13%
Colon & Rectum	10%	8%
Uterus	7%	7%
Thyroid	5%	6%

Table 3

Figure 4 depicts age distribution in comparison with the National Cancer Data Base (NCDB) which is 2013. NCDB data includes cases of 595 Comprehensive Community Cancer Program hospitals. Twenty-eight percent (28%) of patients at CMC were diagnosed between the ages of 70-79 compared to 22% at NCDB.

Age at Diagnosis




Figure 4